AzTrials
AzTrials

Acute Kidney InjuryMARCENCT02332070

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

An observational study of Acute Kidney Injury and Renal Insufficiency, run by Baylor Research Institute at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and… Read more about this study

Who is it for?
Any age
Conditions the study is for
Acute Kidney Injury, Renal Insufficiency
What is being tested?
cardiac surgery
Type of treatment
Surgery or procedure
How many people
965 participants
Where
1 siteUnited States
Study dates
Jan 2015to Feb 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one baseline and postoperative serum creatinine (mg/dl).

Who may be able to join

  • Cardiac surgery with or without cardiac valve surgery
  • At least one baseline and postoperative serum creatinine (mg/dl)

Who cannot join

  • Use of contrast agent other than IOCM with the preoperative angiogram
  • Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
  • Operations where there is implantation of mechanical assist devices or cardiac transplant

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baylor Heart and Vascular Institute

    Dallas, Texas, 75226

Other trials in United States

About this study

Official title: Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)

  1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
  2. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
  3. Thakar Acute Renal Failure (ARF) score (1 to 17)
  4. To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Read the detailed description

Background: Despite advances in cardiac surgical techniques, modern anesthesia, and adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI) remains a frequent and important complication. With advancing age and more severe comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g. Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy (RRT), and are associated major adverse cardiac events with early and later mortality. Mehta and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time between the diagnostic coronary angiogram and the subsequent surgery. This suggested that superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3 days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores could not be computed due to lack of information and those that could have unstable point estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts to improve quality of care have not been applied in a widespread manner to cardiac surgical cases. Thus we propose to evaluate these key concepts in a large dataset which captures important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and associated major adverse renal and cardiac events (MARCE) including the need for RRT, myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death. We aim to derive a practical approach in determining the optimal waiting period from the time of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown to have the lowest risk of CI-AKI.

Specific Aims:

  1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
  2. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
  3. Thakar Acute Renal Failure (ARF) score (1 to 17)
  4. To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality

Methods

Study Design: Retrospective cohort

Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).

Excluded Cases

  1. Use of contrast agent other than IOCM with the preoperative angiogram
  2. Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
  3. Operations where there is implantation of mechanical assist devices or cardiac transplant

Measurements:

  1. CI-AKI will be assessed by several methods during the period from angiography to cardiac surgery:
  2. Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
  3. Conventional composite CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
  4. Conventional singular CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
  5. Conventional singular CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
  6. CSA-AKI will be defined by several methods:
  7. Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
  8. Conventional composite derived from CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
  9. Conventional singular derived from CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
  10. Conventional singular derived from CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
  11. MARCE will be the composite of RRT, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
  12. RRT will include at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
  13. All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
  14. All-cause mortality will be reported as inpatient, 30-day, and one-year
  15. Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
  16. Baseline eGFR will be calculated using the CKD-EPI formula GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black] Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
  17. Clinical factors: age, diabetes, Hb, heart failure, operative variables (bypass time, coronary bypass with valve surgery, on-pump, off-pump) and other predictors of CSA-AKI will be reported in baseline characteristics and considered as candidates for multivariable models
Being tested
cardiac surgery
Keywords
acute kidney injury, coronary angiography, cardiac surgery, adverse events, iodinated contrast, Thoracic Surgery
Medical subject headings
Acute Kidney Injury, Renal Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cardiac surgeryProcedure or surgery

    coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Contrast-induced acute kidney injury

    KDIGO definition

    Measured: 7 days

  2. Cardiac surgery associated acute kidney injury

    KDIGO definition

    Measured: 7 days

  3. Major adverse renal and cardiac events

    Composite of need for renal replacement therapy, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death

    Measured: 30 days

Secondary outcomes (9)
  1. Renal replacement therapy

    at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification

    Measured: 30 days

  2. Myocardial Infarction

    Myocardial infarction as defined by STS

    Measured: 30 days

  3. Stroke

    Stroke as defined by STS

    Measured: 30 days

  4. Heart failure

    Heart failure

    Measured: 30 days

  5. Hospitalization for renal reasons

    Hospitalization for renal reasons

    Measured: 30 days

  6. Hospitalization for cardiac reasons

    Hospitalization for cardiac reaons

    Measured: 30 days

  7. Death

    Death

    Measured: 30 days

  8. All-cause hospitalization

    All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database

    Measured: 30 days

  9. Days out of the hospital and alive

    Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2015 (estimated)
  2. Study startJan 2015
  3. Primary completionFeb 2017
  4. Study completionFeb 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
965 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02332070
Sponsor's protocol ID
014-096
Acronym
MARCE
Status last verified
Feb 2018
First submitted
5 Jan 2015
Last updated
12 Feb 2018
Results posted
No
Data monitoring committee
No

Publications

  • McCullough PA, Brown JR. Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis. Cardiorenal Med. 2011;1(4):220-234. doi: 10.1159/000332384. Epub 2011 Oct 4.

    PubMed 22164156
  • Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol. 2014 Mar;9(3):448-56. doi: 10.2215/CJN.02440213. Epub 2013 Dec 5.

    PubMed 24311708
  • Tecson KM, Brown D, Choi JW, Feghali G, Gonzalez-Stawinski GV, Hamman BL, Hebeler R, Lander SR, Lima B, Potluri S, Schussler JM, Stoler RC, Velasco C, McCullough PA. Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery. Ann Thorac Surg. 2018 Jun;105(6):1724-1730. doi: 10.1016/j.athoracsur.2018.01.010. Epub 2018 Feb 2.

    PubMed 29408241

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury and Renal Insufficiency, run by Baylor Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Contrast-induced acute kidney injury (time frame: 7 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02332070, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in